

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

**GRANT OF RESTRICTED SHARES
PURSUANT TO THE RESTRICTED SHARE AWARD SCHEME**

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”) dated 22 March 2019 (the “**Announcement**”) in relation to the adoption of the restricted share award scheme (the “**Scheme**”) of the Company, a summary of the principal terms of which was set out in the Announcement. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

On 22 March 2019, the Board approved the adoption of the Scheme to (i) provide Selected Participants with the opportunity to acquire proprietary interests in the Company; (ii) encourage the Selected Participants to work towards enhancing the value of the Company and its Shares or the benefit of the Company and its shareholders as a whole; and (iii) provide the Company with a flexible means of either retaining, incentivizing, rewarding, remunerating, compensating and/or providing benefits to the Selected Participants. Details of the Scheme are set out in the Announcement. The Scheme does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules and is a discretionary scheme of the Company.

The Board is pleased to announce that on 19 July 2019, employees of the Company (the “**Grantees**”) were granted 1,048,116 Restricted Shares, subject to acceptance of the Grantee, pursuant to the Scheme (the “**Grant**”). Details of the Grant are set out as follows:

Number of Grant Shares:	1,048,116 Restricted Shares, representing approximately 0.06% of the issued share capital of the Company as at the date of this announcement
Grantees:	Employees of the Company and to the best knowledge of the Directors, none of the Grantees is a director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or associate (as defined in the Listing Rules) of any of them
Date of Grant:	19 July 2019
Market price of the Shares:	The closing price of the Shares on the Stock Exchange as at the date of grant of the Restricted Shares is HK\$18.3 per Share

The Grant Shares have been acquired by the Trustee through on-market transactions and are currently held by the Trustee in accordance with the Rules and the Trust Deed until the end of the relevant Vesting Date and be transferred to the Grantee upon satisfaction of the relevant vesting conditions as may be specified by the Board at the time of making the Grant. As no new Shares will be issued by the Company as a result of the Grant, the Grant will not result in any dilution effect on the shareholdings of existing shareholders of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 19 July 2019

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*